ABVC BioPharma, Inc. (NASDAQ:ABVC) Sees Large Growth in Short Interest

ABVC BioPharma, Inc. (NASDAQ:ABVC) was the target of a large increase in short interest in October. As of October 31st, there was short interest totalling 186,200 shares, an increase of 34.8% from the October 15th total of 138,100 shares. Approximately 1.8% of the company’s stock are sold short. Based on an average daily trading volume, of 135,200 shares, the short-interest ratio is currently 1.4 days.

ABVC BioPharma Price Performance

NASDAQ ABVC opened at $0.54 on Thursday. ABVC BioPharma has a 12 month low of $0.41 and a 12 month high of $2.45. The company has a market capitalization of $6.64 million, a price-to-earnings ratio of -0.32 and a beta of 0.82. The firm’s fifty day moving average price is $0.62 and its 200 day moving average price is $0.76.

ABVC BioPharma (NASDAQ:ABVC) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.09) earnings per share (EPS) for the quarter. ABVC BioPharma had a negative return on equity of 139.97% and a negative net margin of 8,363.97%. The firm had revenue of $0.12 million for the quarter.

ABVC BioPharma Company Profile

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.